Castor oil—based graft copolymers: synthesis, characterization antimicrobial activity and antiproliferative effects against breast cancer cell lines

2022 ◽  
Author(s):  
Sema Alli ◽  
Gorkem Dulger ◽  
Ilker Kiliccioglu ◽  
Abdulkadir Alli ◽  
Basaran Dulger
Keyword(s):  
Breast Cancer ◽  
Antimicrobial Activity ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Castor Oil ◽  
Graft Copolymers ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Antiproliferative Effects

scholarly journals Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines

2013 ◽  
Vol 14 (6) ◽  
pp. 537-545 ◽  
Author(s):  
Aisling Pierce ◽  
Patricia M. McGowan ◽  
Maura Cotter ◽  
Maeve Mullooly ◽  
Norma O’Donovan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Antiproliferative Effects

Synthesis, Characterization and In Vitro Antiproliferative Effects of Novel 5-Amino Pyrazole Derivatives against Breast Cancer Cell Lines

2011 ◽  
Vol 6 (2) ◽  
pp. 186-195 ◽  
Author(s):  
Hanumegowda Raju ◽  
Siddappa Chandrappa ◽  
Doddakunche S. Prasanna ◽  
Hanumappa Ananda ◽  
Tandaga S. Nagamani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Pyrazole Derivatives ◽  
Antiproliferative Effects

The arotinoid Ro 40-8757 has antiproliferative effects in drug-resistant human colon and breast cancer cell lines in vitro

1994 ◽  
Vol 85 (1) ◽  
pp. 83-86 ◽  
Author(s):  
Christophe Louvet ◽  
Sylvie Empereur ◽  
Dominique Fagot ◽  
Elisabeth Forgue-Lafitte ◽  
Eric Chastre ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Human Colon ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Drug Resistant ◽  
Antiproliferative Effects

scholarly journals A Phenylacetamide Resveratrol Derivative Exerts Inhibitory Effects on Breast Cancer Cell Growth

2021 ◽  
Vol 22 (10) ◽  
pp. 5255
Author(s):  
Adele Chimento ◽  
Anna Santarsiero ◽  
Domenico Iacopetta ◽  
Jessica Ceramella ◽  
Arianna De Luca ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Estrogen Receptor ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Molecular Mechanisms ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Antiproliferative Effects

Resveratrol (RSV) is a natural compound that displays several pharmacological properties, including anti-cancer actions. However, its clinical application is limited because of its low solubility and bioavailability. Here, the antiproliferative and anti-inflammatory activity of a series of phenylacetamide RSV derivatives has been evaluated in several cancer cell lines. These derivatives contain a monosubstituted aromatic ring that could mimic the RSV phenolic nucleus and a longer flexible chain that could confer a better stability and bioavailability than RSV. Using MTT assay, we demonstrated that most derivatives exerted antiproliferative effects in almost all of the cancer cell lines tested. Among them, derivative 2, that showed greater bioavailability than RSV, was the most active, particularly against estrogen receptor positive (ER+) MCF7 and estrogen receptor negative (ER-) MDA-MB231 breast cancer cell lines. Moreover, we demonstrated that these derivatives, particularly derivative 2, were able to inhibit NO and ROS synthesis and PGE2 secretion in lipopolysaccharide (LPS)-activated U937 human monocytic cells (derived from a histiocytoma). In order to define the molecular mechanisms underlying the antiproliferative effects of derivative 2, we found that it determined cell cycle arrest at the G1 phase, modified the expression of cell cycle regulatory proteins, and ultimately triggered apoptotic cell death in both breast cancer cell lines. Taken together, these results highlight the studied RSV derivatives, particularly derivative 2, as promising tools for the development of new and more bioavailable derivatives useful in the treatment of breast cancer.

scholarly journals Antiproliferative Effects of Recombinant Apoptin on Lung and Breast Cancer Cell Lines

2020 ◽  
Vol 23 (9) ◽  
pp. 593-599
Author(s):  
Masoud Ezami Razliqi ◽  
Gholamreaza Olad ◽  
Rouhollah Dorostkar ◽  
Sahar Heydari ◽  
Hadi Esmaeili Gouvarchin Ghaleh
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Cell Line ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Mtt Assay ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Antiproliferative Effects

Background: Selective therapy has always been the main challenge in cancer treatments. Various non-replicative oncolytic viral systems have revealed the safety and efficacy of using viruses and these products. The aim of this paper is to examine the impact of recombinant apoptin on the proliferation of lung cancer and breast cancer cell lines. Methods: The present study consisted of two steps of expression of recombinant apoptin and its anti-proliferative effects on normal and cancer cells. In the first step, following bioinformatics and optimizing apoptin gene sequencing and synthesis, it was expressed using vector PET28a and E. coli BL21 (DE3). The expressed recombinant apoptin was confirmed by analytical SDSPAGE and then purified using Ni affinity chromatography. In the second step, the antiproliferative effects of recombinant apoptin on lung cancer, breast cancer and primary cell lines were determined using MTT assay. Results: According to the results of SDS-PAGE gel assay, recombinant apoptin was visible in the 14 kDa band. Also, the MTT assay results indicated that the antiproliferative effects of recombinant apoptin in cancer cell lines was different compared with the primary cell line, and followed a dose-dependent manner in both cell lines. The highest cytotoxicity (lowest cell viability) groups were 0.2 mg/mL in lung cancer (0.32 ± 0.015) (P<0.001), and in breast cancer (0.33 ± 0.031) (P<0.001) and 0.032 mg/mL in primary cells (0.17 ± 0.004) (P<0.01), as compared to the control groups. Conclusion: Our results confirmed that recombinant apoptin can induce antiproliferative effects in lung cancer and breast cancer cell lines, but not in normal monkey kidney cell line Vero; thus, it can be introduced as a promising novel specific antitumor agent after further evaluation in clinical trials.

scholarly journals Evaluation of the antiproliferative effects of the HASPIN inhibitor CHR-6494 in breast cancer cell lines

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0249912
Author(s):  
Hisayo Nishida-Fukuda ◽  
Keizo Tokuhiro ◽  
Yukio Ando ◽  
Hiroaki Matsushita ◽  
Morimasa Wada ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Mammary Epithelial Cells ◽  
Cancer Cell Lines ◽  
Mammary Epithelial ◽  
Breast Cancer Cell Lines ◽  
Antiproliferative Effects

HASPIN is a serine/threonine kinase that regulates mitosis by phosphorylating histone H3 at threonine 3. The expression levels of HASPIN in various cancers are associated with tumor malignancy and poor survival, suggesting that HASPIN inhibition may suppress cancer growth. As HASPIN mRNA levels are elevated in human breast cancer tissues compared with adjacent normal tissues, we examined the growth-suppressive effects of CHR-6494, a potent HASPIN inhibitor, in breast cancer cell lines in vitro and in vivo. We found that HASPIN was expressed in breast cancer cells of all molecular subtypes, as well as in immortalized mammary epithelial cells. HASPIN expression levels appeared to be correlated with the cell growth rate but not the molecular subtype of breast cancer. CHR-6494 exhibited potent antiproliferative effects against breast cancer cell lines and immortalized mammary epithelial cells in vitro, but failed to inhibit the growth of MDA-MB-231 xenografted tumors under conditions that have significant effects in a colorectal cancer model. These results imply that CHR-6494 does have antiproliferative effects in some situations, and further drug screening efforts are anticipated to identify more potent and selective HASPIN inhibition for use as an anticancer agent in breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document